Biomarin Pharma Earnings Report

Investing.com – Biomarin Pharma (NASDAQ: BMRN) reported third quarter EPS of $0.91, exceeding the analyst estimate of $0.53 by $0.38. Revenue for the quarter was $746M, surpassing the consensus estimate of $703.14M.

Guidance

Biomarin Pharma projects FY 2024 EPS between $3.25-$3.35, compared to the analyst consensus of $3.22.

The company anticipates FY 2024 revenue between $2.79B-$2.83B, matching the analyst consensus of $2.80B.

Biomarin Pharma's stock price closed at $69.91, reflecting a -16.97% decline over the last three months and -13.67% over the past twelve months.

Over the last 90 days, there have been 15 positive EPS revisions and 2 negative EPS revisions for Biomarin Pharma. Check out the company's stock price’s past reactions to earnings here.

According to InvestingPro, Biomarin Pharma’s Financial Health score is “great performance.”

Stay informed on all upcoming earnings reports by visiting Investing.com's earnings calendar.